Boston, MA -- (ReleaseWire) -- 06/10/2014 -- Breast Cancer - Pipeline Review, H1 2014
Global Markets Direct's, 'Breast Cancer - Pipeline Review, H1 2014', provides an overview of the Breast Cancer's therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Breast Cancer
, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Breast Cancer
and special features on late-stage and discontinued projects.
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
View Full Report Details and Table of Contents
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- The report provides a snapshot of the global therapeutic landscape of Breast Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Breast Cancer
and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Breast Cancer
products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
Companies Mentioned in this Report: Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., Celsion Corporation, Amgen Inc., Sanofi, AstraZeneca PLC, Eli Lilly and Company, Viralytics Ltd., GlaxoSmithKline plc, Bioniche Life Sciences, Inc., Genentech, Inc., Inovio Pharmaceuticals, Inc., MedImmune, LLC, Biotest AG, Daiichi Sankyo Company, Limited, Merck & Co., Inc., A&G Pharmaceutical, Inc., Generex Biotechnology Corporation, Takeda Pharmaceutical Company Limited, Ipsen S.A., Reliance Life Sciences Pvt. Ltd., MediGene AG, Celltrion, Inc., Bio-Path Holdings, Inc., Histogen, Inc., Egenix, Inc., Millennium Pharmaceuticals, Inc., Hanwha Chemical Corporation, Novartis AG, Samyang Holdings Corporation, Aphios Corporation, BioMarin Pharmaceutical Inc., Chong Kun Dang Pharmaceutical Corp., Chugai Pharmaceutical Co., Ltd., Daewoong Pharmaceutical Co., Ltd., Eisai Co., Ltd., Richter Gedeon Nyrt., rEVO Biologics, GTx, Inc., Jeil Pharmaceutical Co., Ltd., Laboratoires Pierre Fabre SA, Nippon Kayaku Co., Ltd., Ono Pharmaceutical Co., Ltd., Pfizer Inc., Sigma-Tau S.p.A., Taiho Pharmaceutical Co., Ltd., Takara Holdings Inc., Teva Pharmaceutical Industries Limited, Sandoz Inc., Exelixis, Inc., A. Menarini Industrie Farmaceutiche Riunite Srl, Cyclacel Pharmaceuticals Inc., CEL-SCI Corporation, Celgene Corporation, Bayer AG, AntiCancer, Inc., Incyte Corporation, Advaxis, Inc., Alchemia Limited, EntreMed, Inc., GW Pharmaceuticals plc, Harbor Therapeutics, Inc., Momenta Pharmaceuticals, Inc., ValiRx Plc, AEterna Zentaris Inc., Immunomedics, Inc., Genfit SA, Lorus Therapeutics Inc., MEI Pharma, Inc., Basilea Pharmaceutica AG, Bionomics Limited, MultiCell Technologies, Inc., Compugen Ltd., Patrys Limited, Cosmo Pharmaceuticals S.p.A, Critical Outcome Technologies Inc., Medivation, Inc., Mast Therapeutics, Inc., Telik, Inc., Regeneron Pharmaceuticals, Inc., Repros Therapeutics Inc., Oncogenex Pharmaceuticals, Inc., Dendreon Corporation, ProMetic Life Sciences Inc., Progen Pharmaceuticals Limited, TapImmune Inc., JW Pharmaceutical Corporation, Jiangsu Hengrui Medicine Co., Ltd., Provectus Biopharmaceuticals, Inc., Galapagos NV, Synta Pharmaceuticals Corp., Panacea Biotec Limited, Sareum Holdings plc, Oasmia Pharmaceutical AB, Algeta ASA, Dongkook Pharmaceutical Co., Ltd., Galena Biopharma, Inc., NanoCarrier Co., Ltd., Rexahn Pharmaceuticals, Inc., Merrion Pharmaceuticals Plc, Scancell Holdings Plc, MabVax Therapeutics, Inc., Nanobiotix SA, Antigen Express, Inc., Morphotek, Inc., Oryzon Genomics S.A., Spectrum Pharmaceuticals, Inc., Debiopharm International S.A., Chipscreen Biosciences Ltd, CIMAB S.A., Aurigene Discovery Technologies Limited, Supratek Pharma Inc., Meabco A/S, Biotecnol Limited, Fusion Antibodies Ltd, Ganymed Pharmaceuticals AG, Actinium Pharmaceuticals, Inc., Philogen S.p.A., Oxford BioTherapeutics Ltd, Quantum Pharmaceuticals, Multimmune GmbH, Med Discovery SA, Glycotope GmbH, TheRyte Ltd., Priaxon AG, Hutchison MediPharma Limited, Vaxon Biotech, Aileron Therapeutics, Inc., Alethia Biotherapeutics Inc., GenSpera, Inc., Ascenta Therapeutics, Inc., Coronado Biosciences, Inc., Heat Biologics, Inc., MacroGenics, Inc., Antyra, Inc., Ambrx, Inc., Arno Therapeutics, Inc., OncoMed Pharmaceuticals, Inc., Kalos Therapeutics, Inc., Vaccinex, Inc., Pantarhei Bioscience BV, AlphaVax, Inc., Azaya Therapeutics Incorporated, Merrimack Pharmaceuticals, Inc., Amplyx Pharmaceuticals, Inc., Conatus Pharmaceuticals Inc., Deciphera Pharmaceuticals, LLC, Angion Biomedica Corp., Affichem, Jennerex Biotherapeutics, Inc., Axelar AB, Endocyte, Inc., Omnitura Therapeutics Inc., Advenchen Laboratories, LLC, Pharminox Limited, Thrasos, Inc., Syndax Pharmaceuticals, Inc., Immunotope, Inc., Esperance Pharmaceuticals, Inc., TransTech Pharma, Inc., Aegis Therapeutics, LLC, Laboratorios Farmaceuticos Rovi, S.A., Immunovaccine, Inc., Welichem Biotech Inc., Etubics Corporation, Immune Design Corp., NewLink Genetics Corporation, Seek, Cellceutix Corporation, Xcovery, Inc., Pharma Mar, S.A., TVAX Biomedical, Inc., Quintessence Biosciences, Inc., Sirnaomics, Inc., Kinex Pharmaceuticals, LLC, to-BBB technologies BV, Genelux Corporation, GlycoMimetics, Inc., Viventia Biotechnologies Inc., Oncovir, Inc., Nexgenix Pharmaceuticals, LLC, ViroMed Co., Ltd., Keystone Nano, Inc., EndoCeutics, Inc., biOasis Technologies Inc., Advanced Cancer Therapeutics, Zymeworks Inc., Domainex Ltd., Clovis Oncology, Inc., 3-V Biosciences, Inc., Sihuan Pharmaceutical Holdings Group Ltd., Oncolix, Inc., Cancer Therapeutics CRC Pty Ltd, EpiZyme, Inc., Sunshine Biopharma, Inc., Soricimed Biopharma Inc., Recepta Biopharma S.A., ISU ABXIS Co.,Ltd., Bioo Therapeutics, Molecular Templates Inc., Jiangsu Kanion Pharmaceutical Co., Ltd., Almac Discovery Ltd., Recombio, NuCana BioMed Limited, f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H, BHR Pharma, LLC, Pacific Northwest Biotechnology, LLC, Nuvilex, Inc., Incuron, LLC, Terpenoid Therapeutics, Inc., Mebiopharm Co., Ltd., Plantacor, Inc., Pharmicell Co., Ltd., BiOrion Technologies B.V., DEKK-TEC, Inc., Regulon Inc., Shenogen Pharma Group Ltd., Laboratorio Elea S.A.C.I.F. and A, Ascentage Pharma Group Corporation, Ltd., Mabion SA, Miami VA Healthcare System, Ampio Pharmaceuticals, Inc., Genor BioPharma Co., Ltd., PT Dexa Medica, Wuxi MTLH Biotechnology Co. Ltd., Igenica, Inc., Immunophotonics Inc, ElexoPharm GmbH, Trojantec ltd., Kadmon Pharmaceuticals, LLC, Verastem, Inc., Cold Genesys, Inc., Zensun (Shanghai) Sci & Tech Co., Ltd., CureFAKtor Pharmaceuticals. LLC, Kancera AB, Jasco Pharmaceuticals, LLC., Vaxeal Holding SA, Orega Biotech SAS, Generon (Shanghai) Corporation Ltd., Conkwest, Inc., Pharma Two B Ltd, Laurantis Pharma Oy, Visionary Pharmaceuticals, Inc., Arrien Pharmaceuticals, LLC, Qu Biologics Inc., Oncobiologics, Inc., CZ BioMed Corp, Mission Therapeutics Ltd, IMPACT Therapeutics, Inc., CytomX Therapeutics, Inc., Puma Biotechnology, Inc., Io Therapeutics, Inc., Avipep Pty Ltd, StemPar Sciences, Inc., Armour Therapeutics Inc., Oncomatrix, S.L., LondonPharma Ltd, AbbVie Inc., DormaTarg, Inc., Oncology Research International Limited, Oncbiomune, L.L.C., AlphaMab Co., Ltd, Vasgen Limited, MediaPharma s.r.l., Huabo Biopharm Co., Ltd., Paras Biopharmaceuticals Finland Oy, Dong-A Socio Holdings Co Ltd, China Grand Wuhan General Pharmaceutical Research Institu
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Pharmaceuticals research reports at Fast Market Research
You may also be interested in these related reports:
- Metastatic Breast Cancer - Pipeline Review, H1 2014
- Non-Small Cell Lung Cancer - Pipeline Review, H1 2014
- Colon Cancer - Pipeline Review, H1 2014
- Small-Cell Lung Cancer - Pipeline Review, H1 2014
- Cervical Cancer - Pipeline Review, H1 2014
- Metastatic Colorectal Cancer - Pipeline Review, H1 2014
- Bladder Cancer - Pipeline Review, H1 2014
- Endometrial Cancer - Pipeline Review, H1 2014
- Cancer Pain - Pipeline Review, H1 2014
- Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014